CNTA [NASD]
Centessa Pharmaceuticals plc
Index- P/E- EPS (ttm)-2.48 Insider Own1.70% Shs Outstand90.50M Perf Week-5.34%
Market Cap460.91M Forward P/E- EPS next Y-2.13 Insider Trans-2.95% Shs Float83.14M Perf Month7.96%
Income-196.10M PEG- EPS next Q-0.57 Inst Own79.60% Short Float4.17% Perf Quarter-48.20%
Sales- P/S- EPS this Y36.50% Inst Trans3.47% Short Ratio10.99 Perf Half Y-62.91%
Book/sh5.31 P/B0.87 EPS next Y-12.40% ROA- Target Price10.75 Perf Year-80.22%
Cash/sh5.45 P/C0.85 EPS next 5Y- ROE- 52W Range2.88 - 25.98 Perf YTD-59.06%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-82.26% Beta-
Dividend %- Quick Ratio21.40 Sales past 5Y- Gross Margin- 52W Low59.79% ATR0.43
Employees90 Current Ratio21.40 Sales Q/Q- Oper. Margin- RSI (14)47.57 Volatility7.39% 11.08%
OptionableNo Debt/Eq0.16 EPS Q/Q78.00% Profit Margin- Rel Volume0.20 Prev Close4.52
ShortableYes LT Debt/Eq0.16 EarningsMar 30 AMC Payout- Avg Volume315.20K Price4.61
Recom2.00 SMA2011.84% SMA50-22.41% SMA200-56.00% Volume64,003 Change1.99%
Jun-17-22Initiated BMO Capital Markets Outperform $19
Jun-03-22Downgrade Jefferies Buy → Hold $37 → $4
Feb-11-22Initiated Goldman Neutral $12
Jun-23-22 09:55AM  
Jun-17-22 02:35PM  
Jun-11-22 10:06AM  
Jun-06-22 08:00AM  
Jun-05-22 07:00AM  
Jun-03-22 08:29AM  
Jun-02-22 06:29AM  
May-16-22 07:00AM  
Mar-30-22 04:01PM  
Mar-23-22 04:30PM  
Mar-07-22 07:30AM  
Feb-24-22 07:30AM  
Feb-17-22 02:38AM  
Jan-01-22 07:33AM  
Dec-21-21 06:38PM  
Dec-14-21 07:30AM  
Dec-13-21 04:15PM  
Dec-06-21 05:00PM  
Nov-24-21 06:59AM  
Nov-15-21 07:00AM  
Nov-10-21 04:45PM  
Nov-01-21 07:29PM  
10:35AM  
07:30AM  
Oct-18-21 08:00AM  
Oct-05-21 08:00AM  
Oct-04-21 08:00AM  
Sep-29-21 08:47AM  
Sep-09-21 12:01PM  
07:30AM  
Sep-01-21 04:15PM  
Aug-16-21 07:00AM  
Jul-14-21 08:06AM  
Jun-07-21 04:15PM  
04:00AM  
Jun-04-21 04:15PM  
May-27-21 10:49PM  
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAHA SAURABHChief Executive OfficerJun 24Buy4.6310,00046,28438,000Jun 27 09:28 PM
YVER ANTOINEEVP & Chairman of DevelopmentJun 17Sale4.689,20043,036739,697Jun 21 07:23 PM
YVER ANTOINEEVP & Chairman of DevelopmentMay 18Sale5.1064,778330,102748,897May 19 06:01 PM
YVER ANTOINEEVP & Chairman of DevelopmentMay 17Sale5.4220,222109,632813,675May 19 06:01 PM
SAHA SAURABHChief Executive OfficerFeb 02Buy9.745,00048,70028,000Feb 04 08:30 AM
GRAINGER DAVID JChief Innovation OfficerJan 28Buy9.0527,500248,75427,500Feb 01 08:15 PM
De Rubertis FrancescoDirectorDec 02Buy12.8234,326440,0593,936,970Dec 06 05:31 PM
Medicxi Ventures Management (J10% OwnerDec 02Buy12.8234,326440,0593,936,970Dec 06 05:11 PM
De Rubertis FrancescoDirectorDec 01Buy12.6260,304761,0363,903,440Dec 02 05:24 PM
Medicxi Ventures Management (J10% OwnerDec 01Buy12.6260,304761,0363,903,440Dec 02 05:10 PM
Medicxi Ventures Management (J10% OwnerNov 30Buy11.6236,847428,1623,844,535Dec 02 05:10 PM
De Rubertis FrancescoDirectorNov 30Buy11.6236,847428,1623,844,535Dec 02 05:24 PM
Medicxi Ventures Management (J10% OwnerNov 29Buy11.7056,706663,4773,808,543Nov 30 05:11 PM
De Rubertis FrancescoDirectorNov 29Buy11.7056,706663,4773,808,543Nov 30 05:26 PM
De Rubertis FrancescoDirectorNov 26Buy11.3411,817133,9493,753,152Nov 30 05:26 PM
Medicxi Ventures Management (J10% OwnerNov 26Buy11.3411,817133,9493,753,152Nov 30 05:11 PM
KANTOFF AARONDirectorNov 18Buy11.9810,000119,85060,000Nov 18 08:30 PM
Bush Tia LChief Quality OfficerNov 16Buy12.465,00062,3028,000Nov 18 07:00 PM
SAHA SAURABHChief Executive OfficerNov 16Buy12.2823,000282,47223,000Nov 18 07:00 PM